Top Key Companies for Non-Alcoholic Steatohepatitis Biomarkers Market: Genfit, Prometheus Laboratories, Siemens Medical Solutions USA, BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer, Bristol-Myers Squibb Company, NGM Biopharmaceuticals, Gilead Sciences, Perspectum Diagnostics, One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Xeptagen SpA, Boehringer Ingelheim.
Global Non-Alcoholic Steatohepatitis Biomarkers Market Size was estimated at USD 2804.77 million in 2022 and is projected to reach USD 4861.39 million by 2028, exhibiting a CAGR of 9.6% during the forecast period.
Global Non-Alcoholic Steatohepatitis Biomarkers Market Overview And Scope:
The Global Non-Alcoholic Steatohepatitis Biomarkers Market Report 2026 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Non-Alcoholic Steatohepatitis Biomarkers utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2026 and 2035. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis Biomarkers Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-Alcoholic Steatohepatitis Biomarkers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Non-Alcoholic Steatohepatitis Biomarkers market.
Global Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation
By Type, Non-Alcoholic Steatohepatitis Biomarkers market has been segmented into:
Hepatic Fibrosis Biomarkers
Serum Biomarkers
Oxidative Stress Biomarkers
Apoptosis Biomarkers
Others
By Application, Non-Alcoholic Steatohepatitis Biomarkers market has been segmented into:
Hospital
Pharmaceutical Company
Others
Regional Analysis of Non-Alcoholic Steatohepatitis Biomarkers Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Non-Alcoholic Steatohepatitis Biomarkers Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Non-Alcoholic Steatohepatitis Biomarkers market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Non-Alcoholic Steatohepatitis Biomarkers market.
Top Key Companies Covered in Non-Alcoholic Steatohepatitis Biomarkers market are:
Genfit
Prometheus Laboratories
Siemens Medical Solutions USA
BioPredictive
Quest Diagnostics
AstraZeneca Plc.
Laboratory Corporation of America Holdings
Pfizer
Bristol-Myers Squibb Company
NGM Biopharmaceuticals
Gilead Sciences
Perspectum Diagnostics
One Way Liver SL
Enterome SA
Echosens SA
Cisbio Bioassays SAS
Celerion Inc.
Xeptagen SpA
Boehringer Ingelheim
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Non-Alcoholic Steatohepatitis Biomarkers Market by Type
5.1 Non-Alcoholic Steatohepatitis Biomarkers Market Overview Snapshot and Growth Engine
5.2 Non-Alcoholic Steatohepatitis Biomarkers Market Overview
5.3 Hepatic Fibrosis Biomarkers
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Hepatic Fibrosis Biomarkers: Geographic Segmentation
5.4 Serum Biomarkers
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Serum Biomarkers: Geographic Segmentation
5.5 Oxidative Stress Biomarkers
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Oxidative Stress Biomarkers: Geographic Segmentation
5.6 Apoptosis Biomarkers
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2026-2035F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Apoptosis Biomarkers: Geographic Segmentation
5.7 Others
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2026-2035F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others: Geographic Segmentation
Chapter 6: Non-Alcoholic Steatohepatitis Biomarkers Market by Application
6.1 Non-Alcoholic Steatohepatitis Biomarkers Market Overview Snapshot and Growth Engine
6.2 Non-Alcoholic Steatohepatitis Biomarkers Market Overview
6.3 Hospital
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2026-2035F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital: Geographic Segmentation
6.4 Pharmaceutical Company
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2026-2035F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Pharmaceutical Company: Geographic Segmentation
6.5 Others
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2026-2035F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Non-Alcoholic Steatohepatitis Biomarkers Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Non-Alcoholic Steatohepatitis Biomarkers Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Non-Alcoholic Steatohepatitis Biomarkers Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 GENFIT
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 PROMETHEUS LABORATORIES
7.4 SIEMENS MEDICAL SOLUTIONS USA
7.5 BIOPREDICTIVE
7.6 QUEST DIAGNOSTICS
7.7 ASTRAZENECA PLC.
7.8 LABORATORY CORPORATION OF AMERICA HOLDINGS
7.9 PFIZER
7.10 BRISTOL-MYERS SQUIBB COMPANY
7.11 NGM BIOPHARMACEUTICALS
7.12 GILEAD SCIENCES
7.13 PERSPECTUM DIAGNOSTICS
7.14 ONE WAY LIVER SL
7.15 ENTEROME SA
7.16 ECHOSENS SA
7.17 CISBIO BIOASSAYS SAS
7.18 CELERION INC.
7.19 XEPTAGEN SPA
7.20 BOEHRINGER INGELHEIM
Chapter 8: Global Non-Alcoholic Steatohepatitis Biomarkers Market Analysis, Insights and Forecast, 2026-2035
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Hepatic Fibrosis Biomarkers
8.2.2 Serum Biomarkers
8.2.3 Oxidative Stress Biomarkers
8.2.4 Apoptosis Biomarkers
8.2.5 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital
8.3.2 Pharmaceutical Company
8.3.3 Others
Chapter 9: North America Non-Alcoholic Steatohepatitis Biomarkers Market Analysis, Insights and Forecast, 2026-2035
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Hepatic Fibrosis Biomarkers
9.4.2 Serum Biomarkers
9.4.3 Oxidative Stress Biomarkers
9.4.4 Apoptosis Biomarkers
9.4.5 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital
9.5.2 Pharmaceutical Company
9.5.3 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market Analysis, Insights and Forecast, 2026-2035
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Hepatic Fibrosis Biomarkers
10.4.2 Serum Biomarkers
10.4.3 Oxidative Stress Biomarkers
10.4.4 Apoptosis Biomarkers
10.4.5 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital
10.5.2 Pharmaceutical Company
10.5.3 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market Analysis, Insights and Forecast, 2026-2035
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Hepatic Fibrosis Biomarkers
11.4.2 Serum Biomarkers
11.4.3 Oxidative Stress Biomarkers
11.4.4 Apoptosis Biomarkers
11.4.5 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital
11.5.2 Pharmaceutical Company
11.5.3 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Analysis, Insights and Forecast, 2026-2035
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Hepatic Fibrosis Biomarkers
12.4.2 Serum Biomarkers
12.4.3 Oxidative Stress Biomarkers
12.4.4 Apoptosis Biomarkers
12.4.5 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital
12.5.2 Pharmaceutical Company
12.5.3 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Non-Alcoholic Steatohepatitis Biomarkers Market Analysis, Insights and Forecast, 2026-2035
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Hepatic Fibrosis Biomarkers
13.4.2 Serum Biomarkers
13.4.3 Oxidative Stress Biomarkers
13.4.4 Apoptosis Biomarkers
13.4.5 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital
13.5.2 Pharmaceutical Company
13.5.3 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Non-Alcoholic Steatohepatitis Biomarkers Market Analysis, Insights and Forecast, 2026-2035
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Hepatic Fibrosis Biomarkers
14.4.2 Serum Biomarkers
14.4.3 Oxidative Stress Biomarkers
14.4.4 Apoptosis Biomarkers
14.4.5 Others
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospital
14.5.2 Pharmaceutical Company
14.5.3 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Non-Alcoholic Steatohepatitis Biomarkers Scope:
|
Report Data
|
Non-Alcoholic Steatohepatitis Biomarkers Market
|
|
Non-Alcoholic Steatohepatitis Biomarkers Market Size in 2025
|
USD XX million
|
|
Non-Alcoholic Steatohepatitis Biomarkers CAGR 2025 - 2032
|
XX%
|
|
Non-Alcoholic Steatohepatitis Biomarkers Base Year
|
2024
|
|
Non-Alcoholic Steatohepatitis Biomarkers Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Genfit, Prometheus Laboratories, Siemens Medical Solutions USA, BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer, Bristol-Myers Squibb Company, NGM Biopharmaceuticals, Gilead Sciences, Perspectum Diagnostics, One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Xeptagen SpA, Boehringer Ingelheim.
|
|
Key Segments
|
By Type
Hepatic Fibrosis Biomarkers
Serum Biomarkers
Oxidative Stress Biomarkers
Apoptosis Biomarkers
Others
By Applications
Hospital
Pharmaceutical Company
Others
|
